Glaukos has completed patient enrolment of a Phase 2 clinical trial evaluating GLK-321, its investigational drug candidate for the treatment of Demodex blepharitis.
GLK-321 uses a patented, cream-based drug formulation applied to the outer surface of the eyelids to enable dropless, transdermal delivery of pharmaceutically active compounds.
The formulation is designed to improve patient compliance, offer faster onset of action, and reduce side effects and patient burden often associated with traditional eye drop regimens.
The disease is believed to be significantly underdiagnosed and can adversely affect ocular surface health and patient quality of life.
The Phase 2 trial will evaluate safety, tolerability, and efficacy of three different dose levels of GLK-321 in 275 patients with Demodex blepharitis across multiple clinic sites in the United States.
Demodex blepharitis is a chronic eyelid disease associated with demodex mite infestation and is characterised by eyelid inflammation, irritation, redness, itching, and the presence of collarettes at the base of eyelashes.
The disease is believed to be significantly underdiagnosed and can adversely affect ocular surface health and patient quality of life.
